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Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative disease. Increasing evidence supports that
dysregulation of autophagy and mitochondrial function are closely related with PD pathogenesis. In this review, we
briefly summarized autophagy pathway, which consists of macroautophagy, microautophagy and chaperone-mediated
autophagy (CMA). Then, we discussed the involvement of mitochondrial dysfunction in PD pathogenesis. We
specifically reviewed the recent developments in the relationship among several PD related genes, autophagy
and mitochondrial dysfunction, followed by the therapeutic implications of these pathways. In conclusion, we
propose that autophagy activity and mitochondrial homeostasis are of high importance in the pathogenesis of
PD. Better understanding of these pathways can shed light on the novel therapeutic methods for PD prevention
and amelioration.
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Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disease. Although most of PD cases
are sporadic, more than 5 % are inherited [1]. The PD
related genes mainly include (1) SNCA, the gene encoding
α-synuclein, which is the main component of Lewy bodies
[2]; (2) LRRK2, which encodes a multi-domain large pro-
tein. Variable LRRK2 mutants contribute to over 10 % of
familial and about 3 % of sporadic PD cases [3]; (3) PINK1
and Parkin, which are genes involved in mitochondrial
turnover and maintenance. Their mutations are associated
with early-onset PD [4]. (4) DJ-1, whose mutants con-
tribute to 1–2 % of autosomal recessive PD [5].
Given the role of autophagy in the elimination of cellu-
lar dysfunctional proteins/organelles, the contribution of
impaired autphagy to PD has attracted increasing interest.
Accumulating evidence indicates autophagy defects are
involved in the PD pathogenesis. PD related VPS35
D620N mutant inhibits autophagy and impairs the traf-
ficking of the autophagy protein ATG9A [6]. In addition,
in the substantia nigra (SN) of PD patients, aberrant au-
tophagy activity is identified [7]. Inducing autophagy by
manipulating Polo-like kinase 2 or activiting chaperone-
mediated autophagy (CMA) can reduce α-synuclein
aggregation [8, 9]. Finally, PD related neurotoxin 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can
induce autophagy through CDK5-mediated phosphoryl-
ation of endophilin B1 [10]. Rotenone could impair
mitophagy to damage neurons which can be rescued by
DJ-1 overexpression [11].
Recently, increasing reports support the role of mito-
chondrial dysfunction in the degeneration of DA neurons
during PD initiation and progression. Mitochondria are
double membrane organelles and participate in multiple
cellular processes, including calcium homeostasis, energy
supply, metabolic synthesis and apoptosis [12]. Mutations
in mtDNA are more frequent in PD patients when com-
pared with the age-matched population [13]. Interestingly,
one recent study reports that α-synuclein overexpression
augments mitochondrial Ca2+ transient by enhancing
endoplasmic reticulum-mitochondria interactions and
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physiological levels of α-synuclein are essential to main-
tain mitochondrial function and morphology [14].
MPTP and rotenone can disturb mitochondrial function,
impair respiratory chain complex and induce oxidative
stress [15, 16]. Thus, excessive mitochondrial stress in
response to environmental toxins or impaired capability
of neurons to remove damaged mitochondria through
mitophagy may result in the death of neurons.
This review discussed the recent findings in the rela-
tionship among several PD related genes, autophagy and
mitochondrial dysfunction (Table 1).
Autophagy
Autophagy, which derived from the Greek words for
“self-digesting”, refers to the cellular catabolic process
to remove the cytosolic components, including mainly
dysfunctional organelles, misfolded proteins, and sur-
plus or unnecessary cytoplasmic contents to lysosome
for digestion [17].
Autophagy can be divided into three major types:
macroautophagy, microautophagy and chaperone-mediated
autophagy (CMA). This classification is dictated by the
way in which the cellular components are being delivered
to lysosomes [17].
Macroautophagy (MA) is the most common and well
conserved form of autophagy, and enables the bulk deg-
radation of cellular contents [18]. It mainly involves five
steps: initiation, nucleation, elongation, fusion, and deg-
radation [19]. In this process, the pre-autophagosomal
structure (PAS) elongates from membrane of Golgi,
mitochondria or endoplasmic reticulum and sequesters
the cullular contents or organelles to form the autopha-
gosome. Subsequently, the autophagosome fuses with
lysosomes to allow the cargo to be degraded [20].
Mitophagy describes the clearance of damaged mito-
chondria by macroautophagy. Increasing evidence prove
that dysregulation of mitophagy play important roles in
neurodegenerative diseases [21].
Microautophagy is the process in which cytoplastic
contents are directly engulfed into lysosomes for degrad-
ation without an intermediate autophagosome [22]. Also,
microautophagy is constitutionally active under normal
conditions and maintains the turnover of cellular nutrients
via selective degradation of proteins and organelles [23].
Unlike macroautophagy, nutritional deprivation or stress
cannot activate microautphagy [24]. Currently, knowledge
about the role and function of microautophagy, especially
in neurodegenerative disease, is limited and further studies
are needed.
CMA is characterized by the high selectivity in substrates
targeting [25]. The substrates for CMA present a unique
pentapeptide motif, which is known as KFERQ. Notably,
this motif is a pattern recognition motif associated with
the hydrophobicity and charge of amino acid residues,
rather than 100 % compliance with specific amino acid
residues [26]. Interestingly, post-translational modification
could perfect some KFERQ-similar motif for CMA
through changing the hydrophobicity and charge of amino
acid residues [27]. Briefly, CMA can be divided into four
main steps: recognition, unfolding, translocation and deg-
radation [28]. Cytoplastic heat shock cognate protein 70
(Hsc70) binds to the substrates after recognizing the
KFERQ motif and delivers it to lysosomal surface, where
the substrates could be unfolded with the help of Hsc70
and other chaperons. Afer that, the unfolded substrate is
translocated into lysosome via lysosome associated mem-
brane protein type 2A (LAMP2A) for degradation under
the lysosomal acid environment.
Mitochondrial dysfunction in Parkinson’s disease
Although the mechanism underlying PD pathogenesis is
still unclear, mitochondrial dysfunction has been increas-
ingly confirmed to be a vital contributor. The main charac-
terizations of mitochondrial dysfunction include ROS over-
production, ATP depletion, mitochondrial DNA depletion,
caspase release and electron transport complex (ETC.) en-
zyme defection [29]. Neurotoxins applied to establish PD
models, including MPTP and rotenone, damage mitochon-
drial function by inhibiting complex I activity [30]. One
recent study specifically knockouts Ndufs4 gene in mice
midbrain DA neurons and reports significant compromise
in complex I activity. However, Ndufs4 deficit mice show
no obvious neurodegeneration, no loss of striatal innerv-
ation and no movement impairment, but with increased
vulnerability to MPTP, suggesting that impaired complex I
activity is involved in the pathogenesis of PD [31]. Another
study shows that complex I inhibition can lead to abnor-
mal oxidition of optic atrophy 1 (OPA1), which in turn
results in mitochondrial structural abnormalities and
dopaminergic neurodegeneration. All these pathogenic
changes are abolished by OPA1 upregulation, hinting
that OPA1 is a novel therapeutic target for PD [32].
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Mitophagy means the way in which damaged mito-
chondria are eliminated by autophagy. Through mito-
phagy, cells regulate both the number and quality of
mitochondria in response to the metabolic stress. One
recent study using genome-wide RNAi screen identifies
sterol regulatory element binding transcription factor 1
(SREBF1), F-box and WD40 domain protein 7 (FBXW7)
as key regulators for PINK/Parkin pathway, which is
reponsible for mitophagy activition [33]. Moreover,
SREBF1 is considered as a risk locus for sporadic PD
[34]. Thus, this study hints that mitophagy may act as a
common mechanistic link between sporadic and auto-
somal recessive PD. Mutation in F-box domain-
containing protein Fbxo7 is related with early-onset
autosomal recessive PD. One study reports that Fbox7
is involved in mitochondrial maintainance via directly
interaction with Parkin to induce mitophagy, which
further confirms the importance of mitophagy in PD
pathogenesis [35].
Our study shows that the myocyte enhancer factor 2D
(MEF2D) is present in neuronal mitochondria and heat
shock protein 70 (Hsp70) interacts with MEF2D and
mediates its mitochondrial translocation. Mitochondrial
MEF2D is responsible for the expression of the gene
NADH dehydrogenase 6 (ND6), which encodes an essen-
tial component of the complex I. Blocking MEF2D func-
tion leads to impaired complex I activity, oxidative stress
and neuronal death. More importantly, in the postmortem
PD brain samples, both mitochondrial MEF2D and ND6
levels are decreased compared with age-matched controls
[36]. Our further study shows that MPTP caused a signifi-
cant decrease in the half-life and total level of MEF2D
mRNA. Down-regulation of MEF2D mRNA alone can
reduces the viability of SN4741 cells and sensitizes the
cells to neurotoxin [37].
PD-related genes are involved in dysregulation of
autophagy and mitochondria
α-synuclein
α-synuclein is encoded by SNCA and its fibrillar form is
the major component of Lowy bodies [38]. Existence of
hydrophobic non-amyloid β component domain endows
α-synuclein with the propensity to aggregate [39]. Ag-
gregated α-synuclein can trigger neuronal death in PD
[40]. Thus, intensive researches focus on how to prevent
or eliminate the aggregation of α-synuclein. Study show
that ubiquitin proteasome system (UPS) is responsible
for degrading monoubiquitinated α-synuclein, while
macroautophagy is for removing deubiquitinated α-
synuclein [41, 42]. Further study demonstrates, in
normal condition, α-synuclein is mainly degraded by
UPS [43]. Macroautophagy pathway can be activated in
response to increased level of wild type or A53T mutant
α-synuclein [44, 45]. However, some studies show that
increased α-synuclein can impair autophagosome synthe-
sis by inhibiting Rab1a [46]. Also, pre-formed α-synuclein
aggregates compromise autophagosome clearance and are
resistant to degradation by autophagy [47]. The difference
may be derived from the variability of models or different
levels of α-synuclein. Further studies are warranted to
address such discrepancy.
Abnormal α-synuclein level can also disrupt mitophagy.
In PD postmortem brain tissues, α-synuclein accumula-
tion increases oxidative stress and disturbs mitochondrial
function [48]. Moreover, both in vivo and in vitro, ex-
pression of α-isoforms of α-synuclein in neurons causes
the fragmentation of mitochondria, which will eventu-
ally leads to the decline in respiration and neuronal
death [49]. Over-expression of α-synuclein can occur in
mitochondria and disrupt mitochondrial membrane
potential by opening the mitochondrial permeability
transition pore (mPTP), thereby initiating mitophagy
[45]. α-synuclein can activate mPTP via interacting
with either adenylate translocator (ANT) or voltage
dependent anion channel (VDAC) [50, 51]. Further
study found that A53T mutant could impair mitochon-
drial function by residing in mitochondria membrane
as monomers and oligomers [52].
Increasing evidence confirms α-synuclein as a target of
chaperone mediated autophagy (CMA). Hsc70 can
recognize soluble α-synuclein and the affinity between
Hsc70 and α-synuclein fibrils is 5-fold tighter compared
with soluble α-synuclein [53]. One recent study showed
that Hsc70 and Ssa1p work like a tweezer to bind two
domains within α-synuclein [54]. Also, in vitro, one study
shows the uptake of extracellular α-synuclein by neurons
and their retrograde axonal transportation to neuronal
soma. However, Hsc70 chaperones α-synuclein in the
extracellular space and alleviates α-synuclein oligomer
formation [55]. Activating CMA activity via up-regulating
LAMP2A decreases α-synuclein turnover and protects
against α-synuclein over-expression induced neurotoxicity
[9]. Our study showed MEF2D, a transcription activator
identified as neuronal survival factor, is the substrate of
CMA. Wild type or mutant α-synuclein accumulation
compromises normal turnover of MEF2D by CMA and
leads to decrease in the MEF2D DNA binding ability and
neuronal stress, which underlies the neuronal loss of PD
[56]. Thus, enhancing CMA pathway could be a promis-
ing therapeutic strategy for PD treatment.
PINK1/Parkin
PINK1 is a serine/threonine kinase protein and mutations
in PINK1 cause a rare form of autosomal recessive PD
[57]. Parkin containing ubiquitin E3 ligase can ubiquitinate
multiple substrates for degradation. Mutations of Parkin
lead to accumulation of its substrates and are related with
early onset juvenile autosomal recessive PD [58].
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Increasing evidence suggests the PINK1/Parkin path-
way is essential for mitochondrial quality control. One
recent study shows that Parkin ubiquitinates dynamin-
related protein 1 (Drp1) to promote its degradation. Dis-
ruption of this interaction by Parkin mutation leads to
the accumulation of Drp1 and mitochondrial fragmenta-
tion [59]. In Drosophila, both Parkin and PINK null mu-
tants show a significant overall slowing of motichondrial
protein turnover and mitophagy. Failure to remove the
damaged mitochondrial proteins plays an important role
in PD pathogenesis [60]. PINK1 mutation affects mito-
chondrial complex I activity and the maintainance of the
electron transport chain, which disturbs the mitochon-
drial membrane potential [61]. Upregulation of Parkin
protects cells against multiple stresses, including endo-
plasmic reticulum stress, mitochondrial stress, proteo-
toxicity and excitotoxicity [62, 63]. By contrast, loss of
Parkin results in mitochondrial fragmentation, decreased
cellular Ca2+ handling capability and increased cellular
vulnerability to stress [64]. All the above findings dem-
onstrate that deficiency in PINK1/Parkin pathway leads
to mitochondrial dysregulation.
Recent researches on PINK1/Parkin pathway have re-
vealed molecular details for mitochondria protection.
Once the mitochondria are impaired and the membrane
potential gets depolarized, PINK1 will accumulate on
the outer membrane of mitochondria (OMM). A study
showed dimeric PINK1 on OMM can recruit Parkin and
thereby phosphorylates Parkin at Ser65 [65]. Research
using mass spectrometry identified VDACs as the dock-
ing site for Parkin recruitment to the OMM [66]. After
Parkin translocation to mitochondria, many OMM pro-
teins are ubiquitinated by Parkin and in turn recruited
other proteins to initiate mitophagy. Then, these Parkin
labeled mitochondria are brought to lysosomes for deg-
radation. This PINK1/Parkin signaling pathway can be
positively modulated by AF-6, which is lacked in caudate/
putamen and SN of sporadic PD patients [67]. Moreover,
up-regulation of translocation of the OMM (TOMM) can
rescue mitophagy impaired by Parkin mutations, hinting
that TOMM acts as an important regulator in PINK1/
Parkin mediated mitophagy [68]. Despite extensive
research, how autophagy related proteins are recruited
during mitophagy process is still unclear and to what ex-
tent mitophagy dysregulation contributes to PD patho-
genesis remains to be investigated.
LRRK2
Leucine-rich repeat kinase 2 (LRRK2) is one of the generic
contributors to PD. As estimated, variable LRRK2 mutants
contribute to over 10 % of familial and about 3 % of spor-
adic PD cases [69]. So far, over 50 LRRK2 mutations have
been identified in PD patients. Among these, the G2019S
mutation is the most common cause of autosomal
dominant familial PD cases [70]. Also, G2019S mutation
can be found in about 2 % sporadic PD. Thus, exploring
LRRK2 pathogenicity is essential to understand the mo-
lecular mechanisms of PD.
Many reports show a relationship between LRRK2 and
macroautophagy. In kidney of mouse, loss of LRRK2
leads to age-dependent bi-phasic alteration of macroauto-
phagy activity [71]. In human neuroglioma cells, inhibition
of LRRK2 kinase activity can stimulate macroautophagy in
the absence of any alteration in mTOR pathway, suggest-
ing that LRRK2 regulates autophagic activity independent
of mTOR signalings [72]. Consistently, LRRK2 activates a
persistent increase in autophagosome formation through a
calcium associated pathway. Simultaneously, LRKR2
upregulation increases p62 and decreases the number of
acidic lysosomes [73]. Moreover, G2019S mutation in-
creases autophagic vacuoles and shortens neurite length
[74]. The effects of G2019S on neurite length can be abol-
ished by down-regulation of LC3 or Atg7 and enhanced
by autophagy inducer rapamycin, hinting that autophagy
plays an important role in regulation of neurite length
[75]. In fibroblasts, G2019S LRRK2 mutant exacerbates
MPTP-induced cell death dependent of autophagic activity
[76]. Furthermore, a study showed that LRRK2 increases
the number of autophagosomes by activating CaMKK/
AMPK pathway [73]. In addition, G2019S mutation aug-
ments autophagic flux by MEK/ERK signaling [77].
LRRK2 and the PD-associated mutations can be de-
graded by CMA. In normal condition, both UPS and
CMA are responsible for the degradation of wild-type
LRRK2. However, G2019S LRRK2 disrupts degradation by
these pathways [78, 79]. In addition, both wild-type
LRRK2 up-regulation and its mutations inhibit formation
of the CMA translocation complex, thereby suppressing
CMA activity [80, 81]. Subsequently, the normal turnover
of CMA substrates is disrupted. Although LRRK2 mutants
damage CMA process, the detailed relationship with
neuronal loss, especially in animal models, still needs to
be further explored.
In physiological conditions, about 10 % of LRRK2 can
present in the OMM, giving rise to the hypothesis that
LRRK2 mutations might have influence over mitochon-
drial function. Study showed LRRK2 G2019S could lead
to mitochondrial fragments by enhancing mitochondrial
fission via phosphorylating decaprenyl diphosphate syn-
thase subunit 2 Dlp1(Dlp1) [82]. Also, LRRK2 mutants
activate dendritic mitochondrial clearance by autophagy
in neurons [83].
DJ-1
DJ-1 belongs to the peptidase C56 family and acts as a
redox-responsive cytoprotective protein. PD-related DJ-1
mutants are rare and contribute to 1–2 % of autosomal
recessive PD [84].
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DJ-1 can serve as a regulator of autophagy. The effect
of DJ-1 up-regulation on macroautophagy depends on
cell type. In dopaminergic neurons, DJ-1 overexpression
induces ERK-dependent mitophagy and protects against
neurotoxin induced apoptosis [11]. Also, in mouse
embryonic fibroblasts, loss of DJ-1 suppresses basal
autophagy and disrupts mitochondrial dynamics [85].
However, in some cancer cells, DJ-1 deficiency activates
autophagy via JNK signaling [86]. Further studies are
needed to address the relationship between DJ-1/au-
tophagy and DA neuronal loss in the context of PD.
As an anti-oxidative protein, DJ-1 also plays an import-
ant role in regulating mitochondrial function. In human
neuroblastoma M17 cells, DJ-1 wild-type overexpression
induces elongated mitochondria while DJ-1 mutants over-
expression causes mitochondrial fragmentation. Interest-
ingly, DLP1 knockdown in these mutant DJ-1 cells
rescues mitochondrial morphology and function [87].
Also, in DJ-1 knockout cells, autophagy degradation was
impaired and defective mitochondria accumulated [88].
Loss of DJ-1 leads to mitochondrial phenotypes including
reduced membrane potential, increased fragmentation
and accumulation of autophagic markers. Supplementing
DJ-1-deficient cells with glutathione reverses both
mitochondrial and autophagic changes suggesting that
DJ-1 may act to maintain mitochondrial function
during oxidative stress [89].
In our recent study [90], we found that DJ-1, harboring
CMA specific motif, is a direct substrate of CMA and mu-
tation inside the motif can disturb the degradation of DJ-1
through CMA. In addition, we showed UPS is not the pri-
mary mechanism responsible for DJ-1 degradation. More
interestingly, CMA preferentially clears the oxidatively in-
jured DJ-1 and the extensive accumulation of the oxidized
DJ-1 monomer following a reduction of lysosomal and
CMA activity affects the formation or alters the balance of
DJ-1 dimer. Furthermore, CMA-DJ-1 pathway plays a
critical role in maintaining mitochondrial morphology
and function under stress and protects against PD
related neurotoxins induced cytoxicity. Our findings
suggest that CMA/DJ-1 pathway is vital for mitochon-
drial homeostasis and dysregulation of this pathway
may explain the neuronal loss during PD pathogenesis.
Recent findings on autophagy from PD human
tissues
Compared with age-matched AD and control brain sam-
ples, CMA markers LAMP2A and Hsc70 are significantly
decreased in SN and amygdala of PD brains, hinting the
role of autophagy in PD pathogenesis [91]. Furthermore,
in peripheral blood mononuclear cells from PD patients,
Hsc70 protein level is decreased in all PD groups, while
glucocerebrosidase protein level is reduced only in the
genetic PD groups [92]. This study suggests that Hsc70
and glucocerebrosidase may serve as a screening tool for
PD diagnosis. In addition, lysosomal glucocerebrosidase
protein level and enzyme activity are selectively reduced
in the region with increased α-synuclein inside the PD
brain of early stage. The loss of lysosomal glucocerebrosi-
dase is directly related to reduced lysosomal CMA activity,
increased α-synuclein and decreased ceramide, which sug-
gests that compromise in lysosomal function contributes
to PD pathology [93]. One study also shows that the fibro-
blasts from PD patients with the mutation G2019S have
higher level of autophagy compared with wild type
fibroblasts, which contributes to the more vulnerability
to MPP+ [76]. However, another study using the
primary cultured fibroblasts from sporadic PD patients
detects no changes in autophagy [94]. Further, one
study uses iPSC-derived DA neurons from PD patients
with GBA1 mutation and finds that these neurons has
autophagic and lysosomal defects as well as increase in
glucosylceramide and α-synuclein levels [95]. Together,
these findings provide evidence for a link between au-
tophagic/lysosomal system and PD pathogenesis.
Therapeutic implications
Currently, there is no effective treatment to halt the pro-
gression of neuronal loss in PD. Thus, developing effective
therapeutic strategy will be of great importance and will
likely result from a better understanding the relationship
between macroautophagy, CMA, mitochondrial homeo-
stasis and PD pathogenesis.
First, since PD is characterized by the presence of ab-
normal protein aggregation, enhancing macroautophagy
to remove the redundant proteins and/or dysfunctional
organelles is being considered as a potential therapeutic
strategy. In vivo, enhancing autophagic activity through
TFEB or Beclin-1 overexpression protects nigral neurons
against α-synuclein-induced toxicity [96]. Coexpression
of beclin-1 activated autophagy, reduced accumulation
of α-synulein, and ameliorated associated neuritic alter-
ations. The above data support that beclin-1 could be a
promising molecular target for PD treatment. In
addition, some autophagy-inducing chemical agents
have been shown to decrease α-synuclein levels in cell
and animal PD models [97, 98].
Furthermore, modulating CMA activity could provide
benefits for PD treatment. In SH-SY5Y cells, generic over-
expression of LAMP2A induces CMA activity and pro-
tectes DA neurons against α-synuclein neurotoxicity [9].
Moreover, in rat SN, overexpression of LAMP2A via lenti-
virus can reduce total levels of α-synuclein and ameliorate
α-synuclein induced neuronal degeneration and stratal
terminal loss [9]. Also, our data demonstrated restoration
of CMA activity is essential to maintain the normal func-
tion of neuronal survival factor MEF2D, thereby regula-
ting ND6 transcription and promoting mitochondrial
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complex I activity, which protect DA neurons from MPTP
induced neurotoxicity [36, 37]. Furthermore, retinoic acid
derivatives can activate CMA to protect cells against pro-
teotoxicity and oxidative stress [99].
Finally, considering the contribution of mitochondrial
dysfunction to the pathogenesis of PD, restoring it might
be a way to prevent or treat PD. The first attempt is to
enhance mitophagy. In drosophila, overexpression of
Parkin increases mitochondrial activity, reduces proteo-
toxicity and extends lifespan [100]. Also, another pos-
sible way is modulate mitochondrial biogenesis, which
would rejuvenate mitochondrial pool. The peroxisome
proliferator-activated receptor gamma, coactivator 1
alpha (PGC-1α) is a potential target. PGC-1α positively
regulates the expression of genes required for mitochon-
drial biogenesis and the cellular antioxidant responses.
Also, expression of PGC-1α-regulated genes is low in
SN neurons in early PD and overexpression of PGC-1α
could suppress ROS and neurodegeneration [101]. Thus
upregulation of PGC-1α is a candidate neuroprotective
strategy in PD. However, targeted up-regulation of PGC-
1α via adeno-associated virus (AAV) in SN region of
mice showed detrimental effect [102, 103]. Thus, further
studies need to clarify this discrepancy.
Conclusion
Future challenges
In our opinion, autophagy activity and mitochondrial
homeostasis are of high importance in the pathogenesis
of PD. Better understanding of the molecular interaction
between autophagy and mitochondria function can give
rise to novel therapeutic methods for PD prevention and
amelioration. Since hypofunctional autophagy lead to
protein/organelles accumulation while excessive autophagy
activation can cause cell damage even autophagic cell
death. The future challenges are to determine how to
optimize autophagic activity to protect neurons during
PD treatment. Also, challenges exist in identifying the
common molecular pathway underlying the pathogenesis
of multiple neurodegenerative diseases as well as the
detailed molecular interaction between autophagy and
mitochondrial dysfunction, especially in PD.
Abbreviations
ANT: Adenylate translocator; CMA: Chaperone-mediated autophagy;
DA: Dopaminergic; DRP1: GTPase dynamic related protein 1; ETC.: Electron
transport complex; LAMP2A: Lysosome associated membrane protein type
2A; LRRK2: Leucine-rich repeat kinase 2; MA: Macroautophagy; MFN1/
2: Mitofusins 1/2; Miro: Mitochondrial Rho GTPases; MPP: Mitochondrial
processing protease; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;
mPTP: Mitochondrial permeability transition pore; mtDNA: Mitochondrial
DNA; ND6: NADH dehydrogenase 6; OMM: Outer membrane of mitochondria;
PARL: Presenilin-associated rhomboid-like protease; PAS: Pre-autophagosomal
structure; PD: Parkinson’s disease; PGC-1α: peroxisome proliferator-activated
receptor gamma, coactivator 1 alpha; PINK1: PTEN induced putative kinase 1;
ROS: Reactive oxygen species; SN: Substantia nigra; UPS: Ubiquitin proteasome




The works were supported by National Natural Science Foundation of China
(Grant No. 31371400) (Q.Y) and (Grant No. 31671060) (Q.Y).
Availability of data and materials
All data generated or analysed during this study are included in this
published article (see Table 1).
Authors’ contributions
BW made substantial contributions to design and draft the manuscript;
NA and G-DG were involved in revising it critically; QY designed, revised
the muscript; All the authors read and gave final approval of the manu-
script to be published.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Neurosurgery, Tangdu Hospital, The Fourth Military Medical
University, No. 569 Xinsi Road, Baqiao District, Xi’an 710038, Shaanxi Province,
China. 2Department of Neurology, Beth Isreal Deaconess Medical Center,
Harvard Medical School, 330 Brookline Ave, Boston 02215, MA, USA.
Received: 31 August 2016 Accepted: 17 October 2016
References
1. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb
Perspect Med. 2012;2:a008888.
2. Recasens A, Dehay B, Bove J, Carballo-Carbajal I, Dovero S, Perez-Villalba A,
Fernagut PO, Blesa J, Parent A, Perier C, et al. Lewy body extracts from
Parkinson disease brains trigger alpha-synuclein pathology and
neurodegeneration in mice and monkeys. Ann Neurol. 2014;75:351–62.
3. Puschmann A. Monogenic Parkinson’s disease and parkinsonism: clinical
phenotypes and frequencies of known mutations. Parkinsonism Relat Disord.
2013;19:407–15.
4. Kilarski LL, Pearson JP, Newsway V, Majounie E, Knipe MD, Misbahuddin A,
Chinnery PF, Burn DJ, Clarke CE, Marion MH, et al. Systematic review and
UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in
early-onset Parkinson’s disease. Mov Disord. 2012;27:1522–9.
5. Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SM. Neuroprotective
function of DJ-1 in Parkinson’s disease. Oxid Med Cell Longev. 2013;2013:683920.
6. Zavodszky E, Seaman MN, Moreau K, Jimenez-Sanchez M, Breusegem SY,
Harbour ME, Rubinsztein DC. Mutation in VPS35 associated with Parkinson’s
disease impairs WASH complex association and inhibits autophagy. Nat
Commun. 2014;5:3828.
7. Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med.
2013;19:983–97.
8. Oueslati A, Schneider BL, Aebischer P, Lashuel HA. Polo-like kinase 2
regulates selective autophagic alpha-synuclein clearance and suppresses
its toxicity in vivo. Proc Natl Acad Sci U S A. 2013;110:E3945–54.
9. Xilouri M, Brekk OR, Landeck N, Pitychoutis PM, Papasilekas T, Papadopoulou-
Daifoti Z, Kirik D, Stefanis L. Boosting chaperone-mediated autophagy in vivo
mitigates alpha-synuclein-induced neurodegeneration. Brain. 2013;136:2130–46.
10. Wong AS, Lee RH, Cheung AY, Yeung PK, Chung SK, Cheung ZH, Ip NY.
Cdk5-mediated phosphorylation of endophilin B1 is required for induced
autophagy in models of Parkinson’s disease. Nat Cell Biol. 2011;13:568–79.
11. Gao H, Yang W, Qi Z, Lu L, Duan C, Zhao C, Yang H. DJ-1 protects dopaminergic
neurons against rotenone-induced apoptosis by enhancing ERK-dependent
mitophagy. J Mol Biol. 2012;423:232–48.
12. Osellame LD, Blacker TS, Duchen MR. Cellular and molecular mechanisms of
mitochondrial function. Best Pract Res Clin Endocrinol Metab. 2012;26:711–23.
Wang et al. Translational Neurodegeneration  (2016) 5:19 Page 6 of 9
13. Lin MT, Cantuti-Castelvetri I, Zheng K, Jackson KE, Tan YB, Arzberger T, Lees AJ,
Betensky RA, Beal MF, Simon DK. Somatic mitochondrial DNA mutations in
early Parkinson and incidental Lewy body disease. Ann Neurol. 2012;71:850–4.
14. Cali T, Ottolini D, Negro A, Brini M. alpha-Synuclein controls mitochondrial
calcium homeostasis by enhancing endoplasmic reticulum-mitochondria
interactions. J Biol Chem. 2012;287:17914–29.
15. Lee DH, Kim CS, Lee YJ. Astaxanthin protects against MPTP/MPP + −induced
mitochondrial dysfunction and ROS production in vivo and in vitro. Food
Chem Toxicol. 2011;49:271–80.
16. Karuppagounder SS, Madathil SK, Pandey M, Haobam R, Rajamma U,
Mohanakumar KP. Quercetin up-regulates mitochondrial complex-I
activity to protect against programmed cell death in rotenone model
of Parkinson’s disease in rats. Neuroscience. 2013;236:136–48.
17. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo
Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, et al. Guidelines for
the use and interpretation of assays for monitoring autophagy (3rd edition).
Autophagy. 2016;12:1–222.
18. Rabinowitz JD, White E. Autophagy and metabolism. Science. 2010;330:1344–8.
19. Pyo JO, Nah J, Jung YK. Molecules and their functions in autophagy.
Exp Mol Med. 2012;44:73–80.
20. Wong AS, Cheung ZH, Ip NY. Molecular machinery of macroautophagy and
its deregulation in diseases. Biochim Biophys Acta. 2011;1812:1490–7.
21. Vives-Bauza C, Przedborski S. Mitophagy: the latest problem for Parkinson’s
disease. Trends Mol Med. 2011;17:158–65.
22. Mijaljica D, Prescott M, Devenish RJ. Microautophagy in mammalian cells:
revisiting a 40-year-old conundrum. Autophagy. 2011;7:673–82.
23. Li WW, Li J, Bao JK. Microautophagy: lesser-known self-eating. Cell Mol Life Sci.
2012;69:1125–36.
24. Petrovski G, Das DK. Does autophagy take a front seat in lifespan extension?
J Cell Mol Med. 2010;14:2543–51.
25. Kaushik S, Cuervo AM. Chaperone-mediated autophagy: a unique way to
enter the lysosome world. Trends Cell Biol. 2012;22:407–17.
26. Cuervo AM. Chaperone-mediated autophagy: selectivity pays off. Trends
Endocrinol Metab. 2010;21:142–50.
27. Ali AB, Nin DS, Tam J, Khan M. Role of chaperone mediated autophagy
(CMA) in the degradation of misfolded N-CoR protein in non-small cell
lung cancer (NSCLC) cells. PLoS One. 2011;6:e25268.
28. Cai Z, Zeng W, Tao K, E Z, Wang B, Yang Q. Chaperone-mediated autophagy:
roles in neuroprotection. Neurosci Bull. 2015;31:452–8.
29. Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in
Parkinson’s disease: molecular mechanisms and pathophysiological
consequences. EMBO J. 2012;31:3038–62.
30. Martinez TN, Greenamyre JT. Toxin models of mitochondrial dysfunction in
Parkinson’s disease. Antioxid Redox Signal. 2012;16:920–34.
31. Sterky FH, Hoffman AF, Milenkovic D, Bao B, Paganelli A, Edgar D, Wibom R,
Lupica CR, Olson L, Larsson NG. Altered dopamine metabolism and increased
vulnerability to MPTP in mice with partial deficiency of mitochondrial complex
I in dopamine neurons. Hum Mol Genet. 2012;21:1078–89.
32. Ramonet D, Perier C, Recasens A, Dehay B, Bove J, Costa V, Scorrano L, Vila M.
Optic atrophy 1 mediates mitochondria remodeling and dopaminergic
neurodegeneration linked to complex I deficiency. Cell Death Differ.
2013;20:77–85.
33. Ivatt RM, Sanchez-Martinez A, Godena VK, Brown S, Ziviani E, Whitworth AJ.
Genome-wide RNAi screen identifies the Parkinson disease GWAS risk locus
SREBF1 as a regulator of mitophagy. Proc Natl Acad Sci U S A. 2014;111:8494–9.
34. Do CB, Tung JY, Dorfman E, Kiefer AK, Drabant EM, Francke U, Mountain JL,
Goldman SM, Tanner CM, Langston JW, et al. Web-based genome-wide
association study identifies two novel loci and a substantial genetic
component for Parkinson’s disease. PLoS Genet. 2011;7:e1002141.
35. Burchell VS, Nelson DE, Sanchez-Martinez A, Delgado-Camprubi M, Ivatt RM,
Pogson JH, Randle SJ, Wray S, Lewis PA, Houlden H, et al. The Parkinson’s
disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy.
Nat Neurosci. 2013;16:1257–65.
36. She H, Yang Q, Shepherd K, Smith Y, Miller G, Testa C, Mao Z. Direct regulation
of complex I by mitochondrial MEF2D is disrupted in a mouse model of
Parkinson disease and in human patients. J Clin Invest. 2011;121:930–40.
37. Wang B, Cai Z, Lu F, Li C, Zhu X, Su L, Gao G, Yang Q. Destabilization of
survival factor MEF2D mRNA by neurotoxin in models of Parkinson’s
disease. J Neurochem. 2014;130:720–8.
38. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney
DF, Trojanowski JQ, Lee VM. Exogenous alpha-synuclein fibrils induce Lewy
body pathology leading to synaptic dysfunction and neuron death. Neuron.
2011;72:57–71.
39. Horvath I, Weise CF, Andersson EK, Chorell E, Sellstedt M, Bengtsson C,
Olofsson A, Hultgren SJ, Chapman M, Wolf-Watz M, et al. Mechanisms of
protein oligomerization: inhibitor of functional amyloids templates alpha-
synuclein fibrillation. J Am Chem Soc. 2012;134:3439–44.
40. Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, Outeiro TF,
Melki R, Kallunki P, Fog K, et al. alpha-Synuclein propagates from mouse
brain to grafted dopaminergic neurons and seeds aggregation in cultured
human cells. J Clin Invest. 2011;121:715–25.
41. Rott R, Szargel R, Shani V, Bisharat S, Engelender S. alpha-Synuclein
ubiquitination and novel therapeutic targets for Parkinson’s disease.
CNS Neurol Disord Drug Targets. 2014;13:630–7.
42. Popova B, Kleinknecht A, Braus GH. Posttranslational Modifications and
Clearing of alpha-Synuclein Aggregates in Yeast. Biomolecules. 2015;5:617–34.
43. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E,
Hyman BT, McLean PJ, Unni VK. Distinct roles in vivo for the ubiquitin-
proteasome system and the autophagy-lysosomal pathway in the
degradation of alpha-synuclein. J Neurosci. 2011;31:14508–20.
44. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is
degraded by chaperone-mediated autophagy and macroautophagy in
neuronal cells. J Biol Chem. 2008;283:23542–56.
45. Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M,
Zharkovsky A, Kaasik A. Mutant A53T alpha-synuclein induces neuronal
death by increasing mitochondrial autophagy. J Biol Chem. 2011;286:10814–24.
46. Winslow AR, Rubinsztein DC. The Parkinson disease protein alpha-synuclein
inhibits autophagy. Autophagy. 2011;7:429–31.
47. Tanik SA, Schultheiss CE, Volpicelli-Daley LA, Brunden KR, Lee VM. Lewy body-
like alpha-synuclein aggregates resist degradation and impair macroautophagy.
J Biol Chem. 2013;288:15194–210.
48. Imaizumi Y, Okada Y, Akamatsu W, Koike M, Kuzumaki N, Hayakawa H,
Nihira T, Kobayashi T, Ohyama M, Sato S, et al. Mitochondrial dysfunction
associated with increased oxidative stress and alpha-synuclein accumulation
in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain.
2012;5:35.
49. Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K, Munishkina L,
Zhang J, Gardner B, Wakabayashi J, et al. Direct membrane association drives
mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein.
J Biol Chem. 2011;286:20710–26.
50. Zhu Y, Duan C, Lu L, Gao H, Zhao C, Yu S, Ueda K, Chan P, Yang H. alpha-
Synuclein overexpression impairs mitochondrial function by associating
with adenylate translocator. Int J Biochem Cell Biol. 2011;43:732–41.
51. Lu L, Zhang C, Cai Q, Lu Q, Duan C, Zhu Y, Yang H. Voltage-dependent
anion channel involved in the alpha-synuclein-induced dopaminergic
neuron toxicity in rats. Acta Biochim Biophys Sin Shanghai. 2013;45:170–8.
52. Auluck PK, Caraveo G, Lindquist S. alpha-Synuclein: membrane interactions
and toxicity in Parkinson’s disease. Annu Rev Cell Dev Biol. 2010;26:211–33.
53. Pemberton S, Madiona K, Pieri L, Kabani M, Bousset L, Melki R. Hsc70
protein interaction with soluble and fibrillar alpha-synuclein. J Biol Chem.
2011;286:34690–9.
54. Redeker V, Pemberton S, Bienvenut W, Bousset L, Melki R. Identification of
protein interfaces between alpha-synuclein, the principal component of
Lewy bodies in Parkinson disease, and the molecular chaperones human
Hsc70 and the yeast Ssa1p. J Biol Chem. 2012;287:32630–9.
55. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, Glabe C, Hyman BT,
McLean PJ. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein
oligomers and rescues trans-synaptic toxicity. FASEB J. 2011;25:326–36.
56. Yang Q, She H, Gearing M, Colla E, Lee M, Shacka JJ, Mao Z. Regulation
of neuronal survival factor MEF2D by chaperone-mediated autophagy.
Science. 2009;323:124–7.
57. Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson’s disease:
progress and therapeutic implications. Mov Disord. 2013;28:14–23.
58. Rakovic A, Grunewald A, Kottwitz J, Bruggemann N, Pramstaller PP, Lohmann K,
Klein C. Mutations in PINK1 and Parkin impair ubiquitination of Mitofusins in
human fibroblasts. PLoS One. 2011;6:e16746.
59. Wang H, Song P, Du L, Tian W, Yue W, Liu M, Li D, Wang B, Zhu Y, Cao C, et
al. Parkin ubiquitinates Drp1 for proteasome-dependent degradation:
implication of dysregulated mitochondrial dynamics in Parkinson disease.
J Biol Chem. 2011;286:11649–58.
60. Vincow ES, Merrihew G, Thomas RE, Shulman NJ, Beyer RP, MacCoss MJ,
Pallanck LJ. The PINK1-Parkin pathway promotes both mitophagy and
Wang et al. Translational Neurodegeneration  (2016) 5:19 Page 7 of 9
selective respiratory chain turnover in vivo. Proc Natl Acad Sci U S A.
2013;110:6400–5.
61. Morais VA, Haddad D, Craessaerts K, De Bock PJ, Swerts J, Vilain S, Aerts L,
Overbergh L, Grunewald A, Seibler P, et al. PINK1 loss-of-function mutations
affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling.
Science. 2014;344:203–7.
62. Bouman L, Schlierf A, Lutz AK, Shan J, Deinlein A, Kast J, Galehdar Z,
Palmisano V, Patenge N, Berg D, et al. Parkin is transcriptionally regulated
by ATF4: evidence for an interconnection between mitochondrial stress
and ER stress. Cell Death Differ. 2011;18:769–82.
63. Van Laar VS, Roy N, Liu A, Rajprohat S, Arnold B, Dukes AA, Holbein CD,
Berman SB. Glutamate excitotoxicity in neurons triggers mitochondrial and
endoplasmic reticulum accumulation of Parkin, and in the presence of N-
acetyl cysteine, mitophagy. Neurobiol Dis. 2015;74:180–93.
64. Cali T, Ottolini D, Negro A, Brini M. Enhanced parkin levels favor ER-
mitochondria crosstalk and guarantee Ca(2+) transfer to sustain cell
bioenergetics. Biochim Biophys Acta. 2013;1832:495–508.
65. Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity
in Parkinson’s disease. Neuron. 2015;85:257–73.
66. Scarffe LA, Stevens DA, Dawson VL, Dawson TM. Parkin and PINK1: much
more than mitophagy. Trends Neurosci. 2014;37:315–24.
67. Haskin J, Szargel R, Shani V, Mekies LN, Rott R, Lim GG, Lim KL,
Bandopadhyay R, Wolosker H, Engelender S. AF-6 is a positive
modulator of the PINK1/parkin pathway and is deficient in Parkinson’s
disease. Hum Mol Genet. 2013;22:2083–96.
68. Lazarou M, Jin SM, Kane LA, Youle RJ. Role of PINK1 binding to the TOM
complex and alternate intracellular membranes in recruitment and
activation of the E3 ligase Parkin. Dev Cell. 2012;22:320–33.
69. Lubbe S, Morris HR. Recent advances in Parkinson’s disease genetics.
J Neurol. 2014;261:259–66.
70. Dusonchet J, Kochubey O, Stafa K, Young Jr SM, Zufferey R, Moore DJ,
Schneider BL, Aebischer P. A rat model of progressive nigral
neurodegeneration induced by the Parkinson’s disease-associated
G2019S mutation in LRRK2. J Neurosci. 2011;31:907–12.
71. Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y, Si H, Cai H, Bonventre JV,
Shen J. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic
alterations of the autophagy pathway. Mol Neurodegener. 2012;7:2.
72. Manzoni C, Mamais A, Dihanich S, Abeti R, Soutar MP, Plun-Favreau H,
Giunti P, Tooze SA, Bandopadhyay R, Lewis PA. Inhibition of LRRK2
kinase activity stimulates macroautophagy. Biochim Biophys Acta.
2013;1833:2900–10.
73. Gomez-Suaga P, Luzon-Toro B, Churamani D, Zhang L, Bloor-Young D,
Patel S, Woodman PG, Churchill GC, Hilfiker S. Leucine-rich repeat kinase 2
regulates autophagy through a calcium-dependent pathway involving
NAADP. Hum Mol Genet. 2012;21:511–25.
74. Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, Banerjee R, Westerlund M,
Pletnikova O, Glauser L, Yang L, et al. Dopaminergic neuronal loss, reduced
neurite complexity and autophagic abnormalities in transgenic mice
expressing G2019S mutant LRRK2. PLoS One. 2011;6:e18568.
75. Winner B, Melrose HL, Zhao C, Hinkle KM, Yue M, Kent C, Braithwaite AT,
Ogholikhan S, Aigner R, Winkler J, et al. Adult neurogenesis and
neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis.
2011;41:706–16.
76. Yakhine-Diop SM, Bravo-San Pedro JM, Gomez-Sanchez R, Pizarro-Estrella E,
Rodriguez-Arribas M, Climent V, Aiastui A, Lopez de Munain A, Fuentes JM,
Gonzalez-Polo RA. G2019S LRRK2 mutant fibroblasts from Parkinson’s
disease patients show increased sensitivity to neurotoxin 1-methyl-4-
phenylpyridinium dependent of autophagy. Toxicology. 2014;324:1–9.
77. Bravo-San Pedro JM, Niso-Santano M, Gomez-Sanchez R, Pizarro-Estrella E,
Aiastui-Pujana A, Gorostidi A, Climent V, Lopez de Maturana R, Sanchez-
Pernaute R, Lopez de Munain A, et al. The LRRK2 G2019S mutant exacerbates
basal autophagy through activation of the MEK/ERK pathway. Cell Mol Life Sci.
2013;70:121–36.
78. Orenstein SJ, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I, Cortes E,
Honig LS, Dauer W, Consiglio A, et al. Interplay of LRRK2 with chaperone-
mediated autophagy. Nat Neurosci. 2013;16:394–406.
79. Lichtenberg M, Mansilla A, Zecchini VR, Fleming A, Rubinsztein DC. The
Parkinson’s disease protein LRRK2 impairs proteasome substrate clearance
without affecting proteasome catalytic activity. Cell Death Dis. 2011;2:e196.
80. Yue Z, Yang XW. Dangerous duet: LRRK2 and alpha-synuclein jam at CMA.
Nat Neurosci. 2013;16:375–7.
81. Sweet ES, Saunier-Rebori B, Yue Z, Blitzer RD. The Parkinson’s Disease-
Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse
Hippocampus. J Neurosci. 2015;35:11190–5.
82. Niu J, Yu M, Wang C, Xu Z. Leucine-rich repeat kinase 2 disturbs
mitochondrial dynamics via Dynamin-like protein. J Neurochem.
2012;122:650–8.
83. Cherra 3rd SJ, Steer E, Gusdon AM, Kiselyov K, Chu CT. Mutant LRRK2 elicits
calcium imbalance and depletion of dendritic mitochondria in neurons.
Am J Pathol. 2013;182:474–84.
84. Rochet JC, Hay BA, Guo M. Molecular insights into Parkinson’s disease.
Prog Mol Biol Transl Sci. 2012;107:125–88.
85. Krebiehl G, Ruckerbauer S, Burbulla LF, Kieper N, Maurer B, Waak J, Wolburg
H, Gizatullina Z, Gellerich FN, Woitalla D, et al. Reduced basal autophagy
and impaired mitochondrial dynamics due to loss of Parkinson’s disease-
associated protein DJ-1. PLoS One. 2010;5:e9367.
86. Ren H, Fu K, Mu C, Li B, Wang D, Wang G. DJ-1, a cancer and Parkinson’s
disease associated protein, regulates autophagy through JNK pathway in
cancer cells. Cancer Lett. 2010;297:101–8.
87. Wang X, Petrie TG, Liu Y, Liu J, Fujioka H, Zhu X. Parkinson’s disease-
associated DJ-1 mutations impair mitochondrial dynamics and cause
mitochondrial dysfunction. J Neurochem. 2012;121:830–9.
88. Thomas KJ, McCoy MK, Blackinton J, Beilina A, van der Brug M, Sandebring A,
Miller D, Maric D, Cedazo-Minguez A, Cookson MR. DJ-1 acts in parallel to the
PINK1/parkin pathway to control mitochondrial function and autophagy.
Hum Mol Genet. 2011;20:40–50.
89. McCoy MK, Cookson MR. DJ-1 regulation of mitochondrial function and
autophagy through oxidative stress. Autophagy. 2011;7:531–2.
90. Wang B, Cai Z, Tao K, Zeng W, Lu F, Yang R, Feng D, Gao G, Yang Q.
Essential control of mitochondrial morphology and function by
chaperone-mediated autophagy through degradation of PARK7.
Autophagy. 2016;12:1215–28.
91. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, Obeso JA,
Schapira AH. Chaperone-mediated autophagy markers in Parkinson disease
brains. Arch Neurol. 2010;67:1464–72.
92. Papagiannakis N, Xilouri M, Koros C, Stamelou M, Antonelou R, Maniati M,
Papadimitriou D, Moraitou M, Michelakakis H, Stefanis L. Lysosomal
alterations in peripheral blood mononuclear cells of Parkinson’s disease
patients. Mov Disord. 2015;30:1830–4.
93. Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E,
Cooper A, Garner B, Halliday GM. Reduced glucocerebrosidase is associated
with increased alpha-synuclein in sporadic Parkinson’s disease. Brain.
2014;137:834–48.
94. Ambrosi G, Ghezzi C, Sepe S, Milanese C, Payan-Gomez C, Bombardieri CR,
Armentero MT, Zangaglia R, Pacchetti C, Mastroberardino PG, et al.
Bioenergetic and proteolytic defects in fibroblasts from patients with
sporadic Parkinson’s disease. Biochim Biophys Acta. 2014;1842:1385–94.
95. Schondorf DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B,
Sardi SP, Valsecchi M, Hoffmann S, Schwarz LK, et al. iPSC-derived
neurons from GBA1-associated Parkinson’s disease patients show
autophagic defects and impaired calcium homeostasis. Nat Commun.
2014;5:4028.
96. Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Bjorklund A.
TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-
synuclein toxicity. Proc Natl Acad Sci U S A. 2013;110:E1817–26.
97. Shoji-Kawata S, Sumpter R, Leveno M, Campbell GR, Zou Z, Kinch L, Wilkins AD,
Sun Q, Pallauf K, MacDuff D, et al. Identification of a candidate therapeutic
autophagy-inducing peptide. Nature. 2013;494:201–6.
98. Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH, Delgado LM,
Alfaro IE, Bernales S, Verdile G, et al. Latrepirdine stimulates autophagy
and reduces accumulation of alpha-synuclein in cells and in mouse brain.
Mol Psychiatry. 2013;18:882–8.
99. Anguiano J, Garner TP, Mahalingam M, Das BC, Gavathiotis E, Cuervo AM.
Chemical modulation of chaperone-mediated autophagy by retinoic acid
derivatives. Nat Chem Biol. 2013;9:374–82.
100. Rana A, Rera M, Walker DW. Parkin overexpression during aging reduces
proteotoxicity, alters mitochondrial dynamics, and extends lifespan. Proc
Natl Acad Sci U S A. 2013;110:8638–43.
101. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C,
Zheng K, Lin J, Yang W, et al. Suppression of reactive oxygen species
and neurodegeneration by the PGC-1 transcriptional coactivators. Cell.
2006;127:397–408.
Wang et al. Translational Neurodegeneration  (2016) 5:19 Page 8 of 9
102. Clark J, Silvaggi JM, Kiselak T, Zheng K, Clore EL, Dai Y, Bass CE, Simon DK.
Pgc-1alpha overexpression downregulates Pitx3 and increases susceptibility
to MPTP toxicity associated with decreased Bdnf. PLoS One. 2012;7:e48925.
103. Ciron C, Lengacher S, Dusonchet J, Aebischer P, Schneider BL. Sustained
expression of PGC-1alpha in the rat nigrostriatal system selectively impairs
dopaminergic function. Hum Mol Genet. 2012;21:1861–76.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wang et al. Translational Neurodegeneration  (2016) 5:19 Page 9 of 9
